Neurocrine

Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
BioSpace
Neurocrine
neuropsychiatric
clinical trials
focal onset seizures
major depressive disorder
NBI-921352
NBI-1065846
Flag link:
Neurocrine's pediatric phase 3 data are missing piece of puzzle for hyperplasia drug submission
Neurocrine's pediatric phase 3 data are missing piece of puzzle for hyperplasia drug submission
Fierce Biotech
Neurocrine
hyperplasia
clinical trials
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo
Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo
Fierce Pharma
Neurocrine
Ingrezza
FDA
Huntington's disease
Teva Pharmaceutical
Flag link:
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
Flag link:
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Flag link:
Neurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab
Neurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab
Fierce Biotech
Voyager Therapeutics
Neurocrine
capsids
CNS
Parkinson's Disease
Flag link:
Neurocrine's $50M bet on Idorsia drug flames out in second PhII
Neurocrine's $50M bet on Idorsia drug flames out in second PhII
Endpoints
Neurocrine
Idorsia
clinical trials
NBI-827104
epileptic encephalopathy
Flag link:
Few safe havens surface in another down quarter for biopharma
Few safe havens surface in another down quarter for biopharma
EP Vantage
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
Flag link:
Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front
Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front
MedCity News
AbbVie
Neurocrine
neurological disorders
Flag link:
Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll
Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll
Fierce Pharma
Horizon Therapeutics
Roche
Genentech
AbbVie
Neurocrine
employee satisfaction
Flag link:
A closely watched schizophrenia drug fails key test
A closely watched schizophrenia drug fails key test
BioPharma Dive
Neurocrine
schizophrenia
Takeda
clinical trials
luvadaxistat
Flag link:
Neurocrine Terminates Parkinson's Deal with Voyager Following Clinical Hold
Neurocrine Terminates Parkinson's Deal with Voyager Following Clinical Hold
BioSpace
Voyager Therapeutics
Parkinson's Disease
Neurocrine
clinical trials
Flag link:
Pandemic Delays Neurocrine’s Drug Launch for Parkinson’s Disease
Pandemic Delays Neurocrine’s Drug Launch for Parkinson’s Disease
BioSpace
Neurocrine
drug launches
Ongentys
Parkinson's Disease
pandemic
COVID-19
Flag link:
Neurocrine Biosciences Q1 Beats on Earnings, Revenue
Neurocrine Biosciences Q1 Beats on Earnings, Revenue
Motley Fool
Neurocrine
earnings
Flag link:
FDA Approves Neurocrine Biosciences' Parkinson's Drug
FDA Approves Neurocrine Biosciences' Parkinson's Drug
Motley Fool
Neurocrine
FDA
Ongentys
Parkinson's Disease
Flag link:
Coronavirus puts on hold launch plans for Neurocrine's Parkinson's drug
Coronavirus puts on hold launch plans for Neurocrine's Parkinson's drug
Biopharma Dive
Neurocrine
Parkinson's Disease
drug launches
COVID-19
pandemic
Flag link:
Go or no go? Covid-19 upstages US regulatory decisions
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Flag link:
Top 7 Companies in Biotech Beach by Revenue
Top 7 Companies in Biotech Beach by Revenue
BioSpace
Biotech Beach
San Diego
California
Amgen
Neurocrine
Acadia Pharmaceuticals
Retrophin
Tocagen
Mirati Therapeutics
AnaptysBio
Flag link:
Neurocrine is beefing up its pipeline, splurging $50M on rights to an epilepsy drug
Neurocrine is beefing up its pipeline, splurging $50M on rights to an epilepsy drug
Endpoints
Neurocrine
epilepsy
Xenon
XEN901
Flag link:

Pages